B
Brian Walker
High Impact
Manager, Controls and Grid-Edge Decarbonization
staff
43 h-index
487 pubs
7,636 cited
Research Areas
Links
Biography and Research Information
Metrics
- h-index: 43
- Publications: 487
- Citations: 7,636
Selected Publications
-
Solvent-Free and Microwave-Assisted Synthesis Enables Formation of Imidazole and Pyrazole Derivatives Through Epoxide Ring Opening (2025)
-
Dehydrogenative Conversions of Aldehydes and Amines to Amides Catalyzed by a Nickel(II) Pincer Complex (2023)
Collaboration Network
Top Collaborators
Dickran Kazandjian
Sylvester Comprehensive Cancer Center (US)
7 shared publications
- Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: The flagship study
- Multiomic evidence of coordinated complex rearrangements, enhancer hijacking, and epigenomic signatures in the first whole-chromosome-phased myeloma genomes
- A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)
- Single-cell DNA sequencing uncovers synergistic co-mutations in multiple myeloma
- Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma
Showing 5 of 7 shared publications
Benjamin Diamond
Sylvester Comprehensive Cancer Center (US)
7 shared publications
- Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: The flagship study
- Multiomic evidence of coordinated complex rearrangements, enhancer hijacking, and epigenomic signatures in the first whole-chromosome-phased myeloma genomes
- A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)
- Single-cell DNA sequencing uncovers synergistic co-mutations in multiple myeloma
- Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma
Showing 5 of 7 shared publications
Marcella Kaddoura
Sylvester Comprehensive Cancer Center (US)
7 shared publications
- Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: The flagship study
- Cyclin D1 beyond the cell cycle: A new role in t(11;14) multiple myeloma
- A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)
- Single-cell DNA sequencing uncovers synergistic co-mutations in multiple myeloma
- Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma
Showing 5 of 7 shared publications
Stephanie Fernandes
Sylvester Comprehensive Cancer Center (US)
6 shared publications
- Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: The flagship study
- A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)
- Single-cell DNA sequencing uncovers synergistic co-mutations in multiple myeloma
- Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma
- A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study)
Showing 5 of 6 shared publications
James E. Hoffman
Sylvester Comprehensive Cancer Center (US)
5 shared publications
- Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: The flagship study
- Multiomic evidence of coordinated complex rearrangements, enhancer hijacking, and epigenomic signatures in the first whole-chromosome-phased myeloma genomes
- A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)
- Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma
- A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study)
Michelle Armogan
Sylvester Comprehensive Cancer Center (US)
5 shared publications
- Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: The flagship study
- A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)
- Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma
- A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study)
- Individualized treatment risk stratification using histopathology-based genomics prediction in multiple myeloma: A multicenter Study in 1429 participants
Stephanie Mompoint
Sylvester Comprehensive Cancer Center (US)
4 shared publications
- Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: The flagship study
- A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)
- Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma
- A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study)
K Koubek
Sylvester Comprehensive Cancer Center (US)
4 shared publications
- Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: The flagship study
- A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)
- Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma
- A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study)
S. Gutiérrez
Sylvester Comprehensive Cancer Center (US)
4 shared publications
- Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: The flagship study
- A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)
- Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma
- A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study)
C. Caballero Díaz
Sylvester Comprehensive Cancer Center (US)
4 shared publications
- Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: The flagship study
- A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)
- Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma
- A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study)
Abhishek Pandey
Sylvester Comprehensive Cancer Center (US)
4 shared publications
- Multiomic evidence of coordinated complex rearrangements, enhancer hijacking, and epigenomic signatures in the first whole-chromosome-phased myeloma genomes
- Single-cell DNA sequencing uncovers synergistic co-mutations in multiple myeloma
- Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma
- Individualized treatment risk stratification using histopathology-based genomics prediction in multiple myeloma: A multicenter Study in 1429 participants
Timothy Ferguson
3 shared publications
- Novel Inhibitors and Activity-Based Probes Targeting Trypsin-Like Serine Proteases
- Novel inhibitors and activity-based probes targeting serine proteases
- Inhibition of Protease–Epithelial Sodium Channel Signaling Improves Mucociliary Function in Cystic Fibrosis Airways
James Reihill
3 shared publications
- Novel Inhibitors and Activity-Based Probes Targeting Trypsin-Like Serine Proteases
- Novel inhibitors and activity-based probes targeting serine proteases
- Inhibition of Protease–Epithelial Sodium Channel Signaling Improves Mucociliary Function in Cystic Fibrosis Airways
Lorraine Martin
3 shared publications
- Novel Inhibitors and Activity-Based Probes Targeting Trypsin-Like Serine Proteases
- Novel inhibitors and activity-based probes targeting serine proteases
- Inhibition of Protease–Epithelial Sodium Channel Signaling Improves Mucociliary Function in Cystic Fibrosis Airways
Enze Liu
Indiana University – Purdue University Indianapolis (US)
3 shared publications
- Characterizing the Molecular Impact of DIS3 Mutation-Driven Mechanisms in Multiple Myeloma
- Multiomic evidence of coordinated complex rearrangements, enhancer hijacking, and epigenomic signatures in the first whole-chromosome-phased myeloma genomes
- Long-read direct RNA-seq reveals dynamic MM transcriptome made of novel isoforms and post-transcriptional modifications